LifeCell gets DCGI approval for clinical trial of Mesocel to treat COVID patients
New Delhi: Stem cell bank LifeCell on Thursday said it has received approval from the Drug Controller General of India (DCGI) for a clinical trial of Mesocel to treat patients with moderate to severe COVID-19.
The company has received the approval for the clinical trial of Mesocel, a new therapy derived from mesenchymal stem cells of the umbilical cord tissue, set to treat patients suffering from COVID 19 pneumonia and acute respiratory distress, from the Biological Division of the DCGI, LifeCell said in a statement.
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe COVID-19, it added.
"This new cell therapy utilising the potent anti-inflammatory, immune-modulating and tissue regenerative properties of Mesenchymal Stem Cells (MSCs) will further strengthen our fight against COVID-19 and help save lives, which is our primary objective," LifeCell Managing Director Mayur Abhaya quoted as saying by PTI.
The company has set up a manufacturing facility at its Chennai campus that will further bolster its biologics manufacturing capabilities, LifeCell said.
Equipped with multiple bioreactors of different sizes, the facility ensures an uninterrupted supply of MSCs for timely and affordable treatment by using the bio-reactors to expand the cells in a sterile environment, thereby providing significant advantages from a cost and quality-control perspective, it added.
Read also: New brand names authorized for 3 Covid-19 vaccines in Canada, Details
Lifecell, a stem cell bank was established in 2004 in technological collaboration with Cryo-Cell International.
The company has state-of-the-art laboratories at Chennai and Gurgaon and a network spread over 200 service centres in the country.
It established its Diagnostics division in 2017 providing comprehensive diagnostic program for mother and baby care, offering preconception, prenatal and newborn testing services.
Further, in 2018, LifeCell Introduced its Biologics division by launching a series of products derived from placental tissues which have well-established applications in clinical settings to provide solutions that enhance patient life expectancy and reduce global disease burden.
